Press Releases :: Avalo Therapeutics, Inc. (AVTX)

Jul 16, 2024 7:00 am EDT

Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer

Jul 9, 2024 7:00 am EDT

Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa

Jun 24, 2024 4:01 pm EDT

Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer

Jun 17, 2024 7:30 am EDT

Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit

May 13, 2024 7:30 am EDT

Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates

Apr 2, 2024 7:00 am EDT

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Mar 29, 2024 4:01 pm EDT

Avalo Reports 2023 Financial Results and Provides Business Updates

Mar 27, 2024 4:01 pm EDT

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

Dec 27, 2023 7:00 am EST

Avalo Therapeutics Announces 1-for-240 Reverse Stock Split

Dec 7, 2023 7:00 am EST

Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split